EVM
KRTX

Eaton Vance Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Eaton Vance Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-49
Closed -$6K – 3074
2021
Q1 		$6K Buy
+49
New +$5.55K ﹤0.01% 2554

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Eaton Vance Management's KRTX Position: Q2 2021 in Review

Eaton Vance Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2021, closing a stake of 49 shares — an estimated $6K sold.

Eaton Vance Management first reported a position in KRTX in Q1 2021 and held it in 1 quarter. The position peaked at $6K in Q1 2021. 159 funds tracked by Wall St. Rank hold KRTX as of Q2 2021.

  • Eaton Vance Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Eaton Vance Management sold 49 Karuna Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $6K.
  • Eaton Vance Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Eaton Vance Management's Karuna Therapeutics, Inc. Common Stock position peaked at $6K in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Eaton Vance Management's 13F filing for Q2 2021, filed 16 Aug 2021.